RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Nice presentation at the Biotech Showcase on Tuesday, see link below from Cortex's website -


http://www.cortexpharm.com/investors/index.html



Dr. Lippa said they are currently finalizing the IND applications for the two CX-1739 Phase 2s in opiate and propofol induced Respiratory Depression. He expects the opiate RD study to start by the end of this quarter and complete in Q3, and the propofol Phase 2 will start in Q3 and complete in Q4.

He also discussed new positive preclinical data for Ampakines in animal models of Pompe Disease and Perinatal/Infant Apnea. He said they are planning a small Phase 2a Pompe clinical study to start mid-2015 and complete by year end. Pompe Disease is a genetic disorder associated with impaired respiration -


Pompe Disease -

http://en.wikipedia.org/wiki/Glycogen_storage_disease_type_II


Work is also progressing on the water soluble/injectible Ampakine CX-1942, with the preclinical studies to be completed by the end of Q2.

Also, the ongoing Dronabinol Phase 2b Sleep Apnea study is due to have topline data by the beginning of the 3rd quarter 2015.

All in all it sounds like Cortex is entering a very exciting period. Dr. Lippa has a very aggressive clinical timeline, which was reaffirmed in this week's presentation, so now we just need to see where the funding will come from to make it all happen.